7 active not recruiting, 2 not yet recruiting, 2 recruiting, 2 terminated. 14 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Active not recruiting 7, Not yet recruiting 2, Recruiting 2, Terminated 2, Completed 1 |
| Phase 1 | 8 | Active not recruiting 4, Terminated 2, Completed 1, Recruiting 1 |
Follow Unresectable Malignant Solid Neoplasm: new trials by email Literature Review of Unresectable Malignant Solid Neoplasm trials Research Report on Unresectable Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2023-09-22 | 2026-08-24 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-10-30 |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 88 | 2022-11-14 | 2026-09-25 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001 - Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Terminated | University of Southern California | 2 | 2021-04-29 | 2026-04-17 |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor Pembrolizumab, Pevonedistat - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2021-03-29 | 2022-12-27 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2020-07-17 | 2026-10-27 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 103 | 2020-04-07 | 2026-10-02 |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Avelumab, Berzosertib - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 23 | 2020-03-17 | 2026-06-11 |
| Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2019-12-14 | 2026-07-31 |
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2014-03-26 | 2026-09-11 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Biopsy, Biospecimen Collection, Computed Tomography - Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2013-10-08 | 2025-01-14 |
Neoplasm Metastasis (13) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Transitional Cell (3) · Endometrial Neoplasms (3) · Melanoma (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Merkel Cell (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Pancreatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Biliary Tract Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1)
Neoplasms (13) · Neoplastic Processes (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Neoplasms by Site (7) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Neoplasms by Histologic Type (5) · Carcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Neoplasms, Glandular and Epithelial (4)
Specimen Handling (10) · Biopsy (8) · Magnetic Resonance Spectroscopy (7) · X-Rays (3) · Nivolumab (2) · Paclitaxel (2) · Taxes (2) · avelumab (2) · ipatasertib (2) · pembrolizumab (2) · trametinib (2) · Alpelisib (1) · CTLA-4 Antigen (1) · CYT003-QbG10 (1) · Colony-Stimulating Factors (1)
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (2) · Fred Hutchinson Cancer Center (1) · Haihua Yuan (1) · Mayo Clinic (1) · University of Southern California (1)
United States (12) · Puerto Rico (2) · Canada (1) · Uganda (1)
Timothy A Yap (3) · Antoni Ribas (1) · Diana L Hanna, MD (1) · Funda Meric-Bernstam (1) · James M Ford (1) · Kristen R Spencer (1) · Michael J Overman (1) · Reva K Basho (1) · Ryan B Corcoran (1) · Shailender Bhatia, MD (1) · Yanyan Lou, MD, PhD (1)
UM1CA186688 (3), U10CA180888 (2), P30CA006516 (1), P30CA014089 (1), P50CA127003 (1), U01CA062490 (1), U10CA032102 (1), U10CA180820 (1), U10CA180830 (1), UM1CA186644 (1), UM1CA186709 (1), UM1CA186716 (1)